Drug resistant tuberculosis is increasing world-wide. Resistance against isoniazid (INH),
rifampicin (RIF), or both (multi-drug resistant TB, MDR-TB) is of particular concern, since INH …

While active tuberculosis (TB) is a treatable disease, many complex factors prevent its global
elimination. Part of the difficulty in developing optimal therapies is the large design space of …

Background Improvement in tuberculosis treatment regimens requires selection of
antibiotics and dosing schedules from a large design space of possibilities. Incomplete …

Tuberculosis (TB) remains as one of the world's deadliest infectious diseases despite the
use of standardized antibiotic therapies. Recommended therapy for drug-susceptible TB is …

Granulomas play a centric role in tuberculosis (TB) infection progression. Multiple
granulomas usually develop within a single host. These granulomas are not synchronized in …

Treatment failure after therapy of pulmonary tuberculosis (TB) infections is an important
challenge, especially when it coincides with de novo emergence of multi-drug-resistant TB …

Tuberculosis (TB) is a major cause of morbidity and mortality worldwide. The emergence
and rapid spread of drug-resistant M. tuberculosis strains urge us to develop novel …

Granulomas are complex lung lesions that are the hallmark of tuberculosis (TB).
Understanding antibiotic dynamics within lung granulomas will be vital to improving and …

Tuberculosis (TB) is a deadly infectious disease caused by Mycobacterium tuberculosis
(Mtb). No available vaccine is reliable and, although treatment exists, approximately 2 …

Mycobacterium tuberculosis associated granuloma formation can be viewed as a structural
immune response that can contain and halt the spread of the pathogen. In several …